List of Excipients in Branded Drug COZAAR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	COZAAR	losartan potassium	0006-0951	CARNAUBA WAX
Merck Sharp & Dohme Corp	COZAAR	losartan potassium	0006-0951	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	COZAAR	losartan potassium	0006-0951	HYDROXYPROPYL CELLULOSE

COZAAR Excipient Strategy and Commercial Opportunities for Losartan Potassium

Last updated: September 24, 2026

Cozaar contains losartan potassium, an oral angiotensin II receptor blocker approved for hypertension, stroke-risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy. Its immediate-release tablet formulation uses a conventional excipient system: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, and a film coating containing hypromellose, hydroxypropyl cellulose, titanium dioxide, and carnauba wax.[1]

The core Cozaar composition is no longer a meaningful exclusivity barrier. Commercial opportunities are concentrated in low-cost generic manufacturing, lactose-free products, orally disintegrating or dispersible tablets, pediatric presentations, fixed-dose combinations, and supply-chain differentiation.

What excipients are used in Cozaar tablets?

Cozaar is a film-coated immediate-release tablet. The formulation is designed for robust tableting, rapid disintegration, acceptable swallowability, and scalable high-volume manufacturing.

Formulation component	Cozaar role	Commercial relevance
Losartan potassium	Active pharmaceutical ingredient and potassium salt	Determines dose, assay, dissolution, and impurity profile
Lactose monohydrate	Diluent and tablet-mass builder	Low cost, but creates suitability concerns for lactose-intolerant or lactose-avoidant patients
Microcrystalline cellulose	Diluent, dry binder, and compression aid	Supports tablet hardness and direct-compression processing
Pregelatinized starch	Binder and disintegration aid	Improves compactability and tablet breakup
Magnesium stearate	Lubricant	Controls ejection force but can slow wetting or dissolution if over-lubricated
Hypromellose	Film-forming coating polymer	Provides surface protection and improves appearance
Hydroxypropyl cellulose	Coating polymer and adhesion aid	Supports coating uniformity
Titanium dioxide	Opacifier and colorant	Improves appearance and light protection
Carnauba wax	Polishing agent	Provides surface finish and handling properties

The exact excipient quantities can vary by strength and manufacturing site. FDA labeling identifies the inactive ingredients but generally does not disclose the complete quantitative formula.[1]

What is the technical role of lactose in Cozaar?

Lactose monohydrate is primarily a cost-effective diluent. It supports tablet weight, flow, and compressibility. Its use also reflects the conventional manufacturing profile of losartan immediate-release tablets.

Lactose creates several commercial constraints:

• It can exclude patients with severe lactose intolerance or excipient avoidance preferences.
• It may create compatibility concerns with certain amine-containing drug substances, although the relevance must be assessed through formulation studies.
• It introduces a distinct supplier and moisture-control requirement.
• It limits positioning as a clean-label, vegan, or lactose-free product.

A lactose-free generic can replace lactose with mannitol, anhydrous dibasic calcium phosphate, additional microcrystalline cellulose, starch, or co-processed excipients. The replacement must preserve tablet hardness, friability, disintegration, dissolution, and stability.

How should a generic manufacturer design a Cozaar-equivalent excipient system?

The lowest-risk strategy is to reproduce the functional behavior of the reference product rather than copy its excipient list. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence, but it generally does not need to use the same inactive ingredients unless an excipient is material to product performance or safety.[2]

Standard low-cost immediate-release formulation

A conventional generic can use:

• Losartan potassium
• Microcrystalline cellulose
• Pregelatinized starch or coprocessed starch
• Lactose monohydrate
• Low-level magnesium stearate
• Hypromellose-based film coating

This approach has the lowest development risk because the excipients are widely available and compatible with high-speed tablet compression. It is appropriate for large-volume tenders, retail generics, and pharmacy substitution.

The principal development risks are over-lubrication, segregation of the active ingredient, tablet sticking, and dissolution drift caused by changes in particle size or granulation moisture.

Lactose-free formulation

A lactose-free product creates a clear commercial distinction from the labeled Cozaar formulation. Suitable alternatives include:

• Mannitol for mouthfeel and rapid wetting
• Microcrystalline cellulose for compactability
• Crospovidone or croscarmellose sodium for rapid disintegration
• Pregelatinized starch for binding and breakup
• Anhydrous dibasic calcium phosphate where high-density tablets are desired

Mannitol-based formulations can support orally disintegrating or chewable presentations, but they may require greater attention to compression force, friability, and moisture protection. Calcium phosphate can improve flow and hardness but may produce a denser tablet with slower disintegration if not balanced with a superdisintegrant.

Direct-compression formulation

Direct compression is commercially attractive because it reduces water exposure, shortens processing time, and lowers equipment requirements. A practical design may use microcrystalline cellulose or a coprocessed filler-binder with a superdisintegrant and low-level lubricant.

Losartan potassium particle engineering is important. Poor flow or broad particle-size distribution can produce dose nonuniformity, especially at the 25 mg strength. Milling, sieving, or controlled agglomeration can improve blend uniformity without adding a wet-granulation step.

What formulation patents protect Cozaar and losartan products?

The original losartan patent estate no longer provides a current commercial barrier to ordinary losartan tablets in the United States.

Asset	Relevance	Status
U.S. Patent No. 5,138,069	Losartan and related angiotensin II receptor antagonist compounds	Expired under the applicable pre-1995 patent-term rules
Cozaar NDA 020386	Losartan potassium tablets	Approved by FDA; generic competition established
Hyzaar NDA 020387	Losartan potassium and hydrochlorothiazide tablets	Separate fixed-dose combination product
Losartan ANDAs	Immediate-release generic tablets	Broad generic supply established

U.S. Patent No. 5,138,069 issued to E. I. du Pont de Nemours and related entities and covered losartan chemistry and related compounds. Its term has expired. The main commercial IP risk therefore comes from later patents covering specific formulations, manufacturing processes, combinations, or delivery systems rather than the basic Cozaar tablet concept.[3]

A current Orange Book review should distinguish between active listings for a particular NDA and expired historical patents. A generic applicant must evaluate all relevant listed patents and use the appropriate ANDA certification, but the ordinary losartan tablet market has already passed the principal patent-expiry event.

When did Cozaar lose exclusivity?

Cozaar lost meaningful U.S. market exclusivity when the core losartan patent protection expired and FDA-approved generic losartan products entered the market. The reference product has since competed against multiple manufacturers and private-label suppliers.

FDA regulatory status

Cozaar is an FDA-approved small-molecule product, not a biologic. Biosimilar regulation does not apply. A competing losartan tablet generally proceeds through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

Generic applicants normally target:

• Same active ingredient: losartan potassium
• Same dosage form: immediate-release tablet
• Same route: oral
• Same strengths: 25 mg, 50 mg, and 100 mg
• Pharmaceutical equivalence
• Comparative dissolution
• In vivo bioequivalence where required
• Stability and impurity control

Pediatric exclusivity does not create a current commercial barrier for standard losartan tablets. New pediatric formulations may require separate regulatory and clinical work, but they do not revive the expired core composition rights.

What commercial opportunities exist for losartan excipient innovation?

The strongest opportunities are product-positioning opportunities rather than exclusivity opportunities.

1. Lactose-free losartan

A lactose-free tablet can target:

• Patients avoiding lactose
• Hospital formularies with excipient restrictions
• Institutional buyers seeking a broader patient-access profile
• Private-label and specialty-pharmacy channels

This is a relatively low-risk development program because it retains the familiar immediate-release tablet architecture.

2. Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, geriatric patients, and patients who have difficulty swallowing conventional tablets. Mannitol, crospovidone, croscarmellose sodium, and low-moisture processing are likely formulation tools.

The product must control:

• Disintegration time
• Mechanical strength
• Tablet friability
• Taste and mouthfeel
• Moisture sensitivity
• Packaging performance

A taste-masked ODT may have greater commercial value than a conventional lactose-free tablet, but it also carries greater development risk. Losartan can have an unpleasant taste, making sweeteners, flavors, ion-exchange resins, polymer coatings, or microencapsulation relevant.

3. Pediatric dispersible formulations

Losartan is used in pediatric hypertension under defined clinical circumstances. A dispersible tablet, granule, or powder-for-suspension product could improve dose flexibility for children who cannot swallow tablets.

Potential excipient systems include:

• Mannitol or sucrose for palatability
• Suspending agents for liquid administration
• Buffer systems for pH control
• Flavoring agents
• Wetting agents
• Unit-dose sachet packaging

The key opportunity is not simply a smaller tablet. Pediatric products need dose flexibility, acceptable taste, accurate dispersion, and stability after reconstitution if a liquid is supplied.

4. Fixed-dose combination products

Losartan is already commercialized in combination with hydrochlorothiazide as Hyzaar. Generic opportunities include:

• Losartan/hydrochlorothiazide
• Losartan/amlodipine
• Losartan with other antihypertensive agents where clinically and regulatorily justified

Combination products reduce pill burden but create additional dissolution, assay, content-uniformity, and stability requirements. Hydrochlorothiazide can impose different moisture and photostability constraints from losartan. A formulation platform that supports both single-agent and combination tablets can reduce manufacturing complexity.

5. Modified-release and adherence products

Modified-release losartan is a weaker near-term opportunity than immediate-release, ODT, or fixed-dose products. Losartan’s established once-daily dosing reduces the clinical need for extended release. A modified-release product would need a clear adherence, tolerability, or pharmacokinetic advantage to justify additional development and regulatory expense.

How strong is the current patent estate for Cozaar?

The core estate is weak from a blocking-rights perspective because the foundational losartan patent has expired and generic substitution is established. The commercial value of new patents would depend on claim scope and clinical differentiation.

Potentially valuable claim categories include:

• Specific ODT compositions
• Taste-masking systems
• Stable liquid or suspension formulations
• Pediatric dosage forms
• Novel co-crystals or solid-state forms
• Manufacturing processes that reduce impurities
• Fixed-dose combinations with defined dissolution profiles
• Packaging systems that improve moisture stability

A patent on a narrow excipient combination may have limited value if competitors can design around it. Stronger protection generally requires a technically specific formulation with measurable performance advantages, supported by comparative data.

Which companies are challenging or competing with Cozaar?

The losartan market is supplied by multiple generic manufacturers. Competition has historically included large generic companies, branded-generic suppliers, and contract manufacturers. The relevant commercial competitors are manufacturers with:

• FDA-approved losartan ANDAs
• Reliable API sourcing
• Low-cost tablet production
• National wholesaler access
• Hospital and Medicaid contracting capability
• Stable supply during API disruptions

Because the market is mature, price and supply reliability usually matter more than brand recognition. A new entrant without a formulation distinction faces substantial price pressure.

What generic launch risks exist for losartan?

Manufacturing and IP barriers

The major barriers are operational rather than foundational patent barriers:

• API price volatility
• Losartan potassium particle-size variation
• Blend uniformity at low dosage strength
• Magnesium stearate over-lubrication
• Dissolution changes after scale-up
• Film-coating defects
• Nitrosamine or other impurity controls
• Supplier qualification for critical excipients
• FDA inspection and data-integrity requirements

Excipient substitution after approval can trigger regulatory reporting or prior-approval requirements depending on the change and its effect on product quality.

Revenue exposure

Cozaar brand revenue is exposed to mature generic substitution. The larger opportunity is aggregate losartan volume across generic tablets and fixed-dose combinations. A conventional generic launch can generate volume but usually has limited pricing power. A differentiated product can command better margins if it secures formulary preference, specialty distribution, or a defined patient-access advantage.

How does Cozaar compare with other angiotensin receptor blockers?

Product	Active ingredient	Formulation opportunity	Market condition
Cozaar	Losartan potassium	Lactose-free tablet, ODT, pediatric dispersible product	Mature generic market
Diovan	Valsartan	Solubility and fixed-dose combination development	Mature generic market
Atacand	Candesartan cilexetil	Solid-state and dissolution control	Mature generic market
Micardis	Telmisartan	High-dose tablet and combination products	Mature generic market
Avapro	Irbesartan	Conventional tablet and combination products	Mature generic market

Losartan has a strong commercial advantage in familiarity, broad prescribing history, and availability in multiple strengths. Its disadvantage is intense generic competition and limited room for premium pricing without a meaningful dosage-form or patient-access improvement.

What licensing and partnering opportunities exist?

Licensing opportunities are most credible in three areas:

1. A differentiated dosage form with issued or prosecutable formulation claims.
2. A pediatric or geriatric product with regulatory development completed.
3. A manufacturing process that lowers cost, improves dissolution consistency, or solves a supply problem.

A license based only on a conventional lactose-free tablet is unlikely to support a large premium. A platform covering taste masking, dispersible delivery, or a stable liquid product has greater partnering potential if supported by bioequivalence, stability, and commercial-scale data.

Key Takeaways

• Cozaar is an immediate-release losartan potassium tablet using a conventional lactose-based excipient system.
• The original losartan patent protection has expired, and the core product has no meaningful composition-of-matter exclusivity barrier.
• The best excipient opportunities are lactose-free tablets, ODTs, pediatric dispersible products, and fixed-dose combinations.
• Generic approval depends on pharmaceutical equivalence, dissolution, bioequivalence, stability, and manufacturing control, not exact replication of the Cozaar excipient list.
• Biosimilar risk does not apply because losartan is a small molecule.
• Commercial returns from a conventional losartan generic are likely to be volume-driven and price-sensitive.
• New patent value would depend on narrow but defensible formulation, manufacturing, or delivery claims.
• The main launch risks are API variability, low-dose blend uniformity, dissolution drift, impurity control, supplier reliability, and generic price competition.

FAQs

Is lactose present in Cozaar?

Yes. The FDA labeling for Cozaar identifies lactose monohydrate among the inactive ingredients.[1]

Can a generic losartan product be lactose-free?

Yes. A generic manufacturer can use alternative diluents such as mannitol, microcrystalline cellulose, starch, or dibasic calcium phosphate, provided the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and stability requirements.

Does Cozaar have active Orange Book patent protection?

The foundational losartan patent has expired. Orange Book status must be evaluated against the specific Cozaar NDA and any currently listed patents, but the mature generic market confirms that core losartan protection no longer blocks ordinary generic entry.

Is a losartan orally disintegrating tablet commercially differentiated?

Yes, particularly for patients with dysphagia and pediatric or geriatric use. The main development challenges are taste masking, mechanical strength, moisture protection, and demonstration of comparable exposure.

Are biosimilars relevant to Cozaar?

No. Cozaar contains losartan potassium, a small-molecule active ingredient. Competing products are regulated as generic drugs through the ANDA pathway rather than as biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). Cozaar (losartan potassium) tablets: Prescribing information. FDA/DailyMed.
2. U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format of abbreviated new drug applications. FDA.
3. United States Patent and Trademark Office. (1992). U.S. Patent No. 5,138,069: Imidazole-5-carboxylic acids and derivatives thereof. USPTO.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.